ArticleBritish journal of cancer2013
Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Decision support systems for incurable non-small cell lung cancer: a systematic review.BMC medical informatics and decision making · 2017Pooled it
- Predictors of Mortality in Patients with Advanced Cancer-A Systematic Review and Meta-Analysis.Cancers · 2022Review
- Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis.Journal of cachexia, sarcopenia and muscle · 2021Article
- Prognostic Model to Predict Overall Survival for Metastatic Non-Small Cell Lung Cancer Patients Treated With Chemotherapy Combined With Concurrent Radiation Therapy to the Primary Tumor: Analysis From Two Prospective Studies.Frontiers in oncology · 2021Article
- Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.Translational lung cancer research · 2019Article
- A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer CasesAsian Pacific journal of cancer prevention : APJCP · 2016Article
- Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2015Article
- Infomarkers for transition to goals consistent with palliative care in dying patients.Palliative & supportive care · 2015Article
- Predictive Modeling for End-of-Life Pain Outcome using Electronic Health Records.Advances in data mining. Industrial Conference on Data Mining · 2015Article
- Cachexia Index in Advanced Non-Small-Cell Lung Cancer Patients.Clinical Medicine Insights. Oncology · 2015Article
- A laboratory prognostic index model for patients with advanced non-small cell lung cancer.PloS one · 2014Article
- Predictive Modeling for Comfortable Death Outcome Using Electronic Health Records.Proceedings. IEEE International Congress on Big DataArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFor evidence-based medical practice, well-defined risk scoring systems are essential to identify patients with a poor prognosis. The objective of this study was to develop a prognostic score, the Montreal prognostic score (MPS), to improve prognostication of patients with incurable non-small cell lung cancer (NSCLC) in everyday practice.
methodsA training cohort (TC) and a confirmatory cohort (CC) of newly diagnosed patients with NSCLC planning to receive chemotherapy were used to develop the MPS. Stage and clinically available biomarkers were entered into a Cox model and risk weights were estimated. C-statistics were used to test the accuracy.
resultsThe TC consisted of 258 patients and the CC consisted of 433 patients. Montreal prognostic score classified patients into three distinct groups with median survivals of 2.5 months (95% confidence interval (CI): 1.8, 4.2), 8.2 months (95% CI: 7.0, 9.4) and 18.2 months (95% CI: 14.0, 27.5), respectively (log-rank, P<0.001). Overall, the C-statistics were 0.691 (95% CI: 0.685, 0.697) for the TC and 0.665 (95% CI: 0.661, 0.670) for the CC.
conclusionThe MPS, by classifying patients into three well-defined prognostic groups, provides valuable information, which physicians could use to better inform their patients about treatment options, especially the best timing to involve palliative care teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.